and PAM50 gene expression features of HER2-low breast cancer [published correction appears in NPJ Breast Cancer. 2023 Apr 29;9(1):32. doi: 10.1038/s41523-023-00538-x]. NPJ Breast Cancer. 2021;7(1):1. Published 2021 Jan 4. doi:10.1038/...
[18]Won HS, Ahn J, Kim Y, Kim JS, Song JY, Kim HK, et al.. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean breast cancer society. Breast Cancer Res (2022...
[2] Tarantino P, Jin Q, Tayob N, et al. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncol. 2022;8(8):1177–1183. [3] Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters ...
[10]Peiffer D, Howard FM, Chen N, et al. Epidemiology and prognosis of HER2-low breast cancer (BC) in the National Cancer Data Base (NCDB). 2022 SABCS. Abstract HER2-11. [11]Tarantino P, Jin Q, Tayob N, et al. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-...
[1]Schettini F,Chic N,Brasó-Maristany F,et al.Clinical,pathological,and PAM50 gene expression features of HER2-low breast cancer.NPJ Breast Cancer 2021;7:1-1. [2]Fehrenbacher L,Cecchini RS,Geyer CE Jr,et al.NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy...
1、Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer [published correction appears in NPJ Breast Cancer. 2023 Apr 29;9(1):32]. NPJ Breast Cancer. 2021;7(1):1. ...
Prat A. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: 10.1038/s41523-020-00208-2. Erratum in: NPJ Breast Cancer. 2023 Apr 29;9(1):32. doi: 10.1038/s41523-023-00538-x. PMID: 33397968; PMCID: PMC...
4. Tang L, et al. Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-lowexpression breast cancer: A real-world retrospective study. Front Oncol, 2022. 12: p. 999716. 5. Shi W, et al. Comparison of clinicopathological characteristics and response to neoadjuvantsystemic therapy...
[9]Fernandez AI, Liu M, Bellizzi A, et al. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncol. 2022 Feb 3:e217239. [10]Diéras V, Deluche E, Lusque A,et al. Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 stat...
[7]Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer (2021) 7(1):1. doi: 10.1038/s41523-020-00208-2 ...